Projektdarstellungen auf der Webseite

Jedes von der Gebert Rüf Stiftung geförderte Projekt wird mit einer Webdarstellung zugänglich gemacht, die über die Kerndaten des Projektes informiert. Mit dieser öffentlichen Darstellung publiziert die Stiftung die erzielten Förderresultate und leistet einen Beitrag zur Kommunikation von Wissenschaft in die Gesellschaft.


b-rayZ – AI technology for breast cancer early detection


Für den Inhalt der Angaben zeichnet die Projektleitung verantwortlich.


Dieses von der Gebert Rüf Stiftung geförderte Projekt wird von folgenden weiteren Projektpartnern mitgetragen:


  • Projekt-Nr: GRS-018/21 
  • Förderbeitrag: CHF 150'000 
  • Bewilligung: 06.05.2021 
  • Dauer: 11.2021 - 12.2023 
  • Handlungsfeld:  InnoBooster, seit 2018



Catching breast cancer at an early stage can save thousands of women every year. Early diagnosis of breast cancer requires profound understanding of the diagnostic procedures and of the pathological features. However, most of the hospitals cannot afford the employment of the few breast specialists on the market and are exposed to high risks of malpractice and to unnecessary costs. Healthcare providers are calling for a technological shift allowing a more efficient and accurate diagnosis of breast cancer.
b-rayZ has developed a ground-breaking platform based on cutting-edge Artificial Intelligence (AI) for flawless and sustainable breast cancer diagnostics. The platform, perfectly aligned with international requirements and the clinical workflow, hosts a portfolio of software products for the evaluation of breast diagnostic imaging to decrease false positive and negative findings. With the InnoBooster grant, b-rayZ has addressed one main factor hindering the adoption of AI solutions at the customer’s site, i.e. the possibility of performing a “calibration” of the AI outputs with the procedures of the client.


With this project, b-rayZ was able to develop an intelligent system that leverages the experience of the few specialists in the world to make the best care available to every patient, everywhere. This is a fundamental step for the further consolidation of our products, already certified as medical devices and available on the market. A close cooperation with main breast imaging centers in Switzerland and Norway will allow the evaluation of the new prototype in different clinical settings. Thanks to the support of the GRF, b-rayZ was able to securing a Serie A funding round. With this investment, the company is approaching larger markets and scaling the commercial activities.


Am Projekt beteiligte Personen

PD Dr. Cristina Rossi, project leader
Dr. Alexander Ciritsis, technical development leader
Prof. Dr. Andreas Boss, clinical specialist

Letzte Aktualisierung dieser Projektdarstellung  18.03.2024